摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-sec-Butyl-2-(3-chloro-4-hydroxy-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one | 352361-58-1

中文名称
——
中文别名
——
英文名称
8-sec-Butyl-2-(3-chloro-4-hydroxy-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
英文别名
8-Butan-2-yl-2-(3-chloro-4-hydroxyanilino)pyrido[2,3-d]pyrimidin-7-one
8-sec-Butyl-2-(3-chloro-4-hydroxy-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one化学式
CAS
352361-58-1
化学式
C17H17ClN4O2
mdl
——
分子量
344.801
InChiKey
KALKGGPTSDJDKF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    78.4
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
    申请人:——
    公开号:US20040224958A1
    公开(公告)日:2004-11-11
    This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-diaminopyrimidines that are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The compounds are readily synthesized and can be administered by a variety of routes, including orally, and have sufficient bioavailability. This invention provides compounds of Formula (I) and Formula (II) where W is NH, S, SO, or SO 2 , R 1 includes phenyl and substituted phenyl, R 2 includes alkyl and cycloalkyl, R 3 includes alkyl and hydrogen, R 8 and R 9 include hydrogen and alkyl, and Z is carboxy. This invention also provide pharmaceutical formulations comprising a compound of Formula (I or II) together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. 1
    这项发明提供了对治疗细胞增殖性疾病(如癌症和再狭窄)有用的吡啶嘧啶和4-嘧啶。我们现在发现了一组7,8-二氢-2(基和吡啶嘧啶和2,4-二嘧啶,它们是细胞周期依赖性激酶(cdk)和生长因子介导的激酶的有效抑制剂。这些化合物易于合成,并且可以通过多种途径(包括口服)给药,具有足够的生物利用度。该发明提供了式(I)和式(II)的化合物,其中W为NH、S、SO或SO2,R1包括苯基和取代苯基,R2包括烷基和环烷基,R3包括烷基和氢,R8和R9包括氢和烷基,Z为羧基。该发明还提供了含有式(I或II)化合物的制剂,与其一起使用的药用可接受载体、稀释剂或赋形剂。
  • PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE
    申请人:WARNER-LAMBERT COMPANY
    公开号:EP1255755A1
    公开(公告)日:2002-11-13
  • [EN] PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE<br/>[FR] DERIVES DE PYRIDOPYRIMIDINONE DESTINES AU TRAITEMENT DE MALADIES MALADIE NEURODEGENERATIVE
    申请人:WARNER LAMBERT CO
    公开号:WO2001055148A1
    公开(公告)日:2001-08-02
    This invention provides a method for treating neurodegenerative diseases in mammals comprising administering an effective amount of a cyclin-dependent kinase inhibitor. A preferred method uses cdk inhibitors of Formula (I) and Formula (II) where W is NH, S, SO, or SO2, R1 includes phenyl and substituted phenyl, R2 includes alkyl and cycloalkyl, R3 includes alkyl and hydrogen, R?8 and R9¿ include hydrogen and alkyl, and Z is carboxy.
查看更多